Traumatic brain injury (TBI) refers to damage to the brain caused by external physical trauma as a result of head injury due to factors such as falls, vehicle accidents, assaults, or sport injuries. The currently available treatment options for TBI include surgical intervention, intensive care unit support, medical devices, and pharmacological therapies such as analgesics, anticonvulsants, and antidepressants. The global Traumatic Brain Injury Therapeutics Market is estimated to be valued at US$ 3.5 Bn in 2024 and is expected to exhibit a CAGR of 34% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The increasing incidences of head injuries due to road accidents, falls or sports injuries have drastically accelerated the cases of TBI over the past few years. As per studies, almost 60% to 90% of all TBI cases in the United States are mild TBIs, also known as concussions. About 10% are moderate or severe. Repeated mild TBI or concussions have been associated with long-term neurological impairment. Thus, the rising cases of TBI are expected to drive the demand for effective TBI therapeutics such as drugs to reduce inflammation, prevent cell death, minimize the effects of brain edema, and improve cognitive functions during the forecast period. Existing therapeutic options have limited efficacy and new drugs are under development to address the unmet needs in TBI treatment. This is further expected to boost the growth of the TBI therapeutics market.

Segment Analysis
The global traumatic brain injury therapeutics market size is segmented by therapeutic, mechanism of action, distribution channel, and geography. The therapeutic segment dominates the market and is further segmented into anti-convulsants, analgesics, anti-depressants, anti-psychotics, and others. The anti-convulsants segment holds the largest market share owing to rising cases of seizures post head injuries.

Key Takeaways
The global traumatic brain injury therapeutics market is expected to witness high growth during the forecast period of 2024 to 2031.

Regional analysis shows that North America is currently the fastest growing region due to rising awareness and presence of advanced healthcare facilities in the region.

Key players operating in the traumatic brain injury therapeutics market are Microsoft, IBM, Dynatrace, Datadog, Splunk, New Relic, GitLab, CircleCI, CloudBees, Snyk, Twistlock, Qualys, Salesforce, SAP, Adobe, Oracle, VMware, Red Hat, Rancher Labs, Sysdig. The market is highly competitive and players are focusing on new product launches and strategic collaborations to gain market share.

Get more insights on this topic: https://www.ukwebwire.com/brain-injury-therapeutics-driven-by-rising-cases-of-head-trauma/